Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
By Clayton D. Harro, Y. Y. Pang, R. Roden, A. Hildesheim, Zhaohui Wang, M. J. Reynolds, T. Mast, Robin A. Robinson, B. Murphy, R. Karron and 3 more. Journal of the National Cancer Institute, 2001
653 citations recorded by the source corpus.
Subfields: Epidemiology, Immunology
View Paper: https://www.semanticscholar.org/paper/68cd0ebb238455fa7a5d354306c308970015e052
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Immunology
Citations in the corpus
- Immune responses to human papillomavirus. (2006, background): “The dominant antibody responses induced by VLP vaccines are of the IgG1 subclass and have been shown to be neutralizing by a variety of surrogate neutralization assays [ 46 ,50,51].”
- Human Papillomavirus and Cervical Cancer (2003, positive): “A double-blind, randomized, placebo-controlled phase I safety and immunogenicity trial has been conducted using a subunit vaccine composed of VLP formed from the entire L1 major capsid protein of HPV-16 strain 114K (45).”
- Human papillomavirus and cervical cancer. (2019, neutral): “In these developing countries, cervical cancer may constitute up to 25% of all female cancer cases [3] and is only preceded by breast cancer as the most common cause of cancer deaths in women worldwide [4].”
- Papillomaviruses and cancer: from basic studies to clinical application (2002, background): “The conclusion of a Phase I safety and immunogenicity trial in adult volunteers of an HPV16L1 VLP vaccine was recently reporte”